Drugs / AC-1101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05580042 | Oct 2022 → Nov 2023 | granuloma annulare | TWi Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC-1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05580042 ↗ |
| Known as | AC-1101 gel | “Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy...” NCT05580042 ↗ |
| Route | Topical | “AC-1101 Topical Gel” NCT05580042 ↗ |